D.1 Summary of Services.xlsx

This is a yearly requirements summary document for compounded sterile pharmaceutical preparations and ancillary supplies required by the VA Heartland Health Care Network (VISN 15) across seven facilities: Columbia, Eastern Kansas, Kansas City, Marion, Poplar Bluff, St. Louis, and Wichita. The document details estimated annual quantities for 76 oncology and specialty pharmaceutical products with their corresponding NDC codes or reference numbers, along with 30 ancillary items including IV tubing, connectors, syringes, sodium chloride solutions, and sterile water for injection. Total annual requirements across all facilities amount to 11,430 units of pharmaceutical products and 32,039 units of ancillary supplies, with a projected contract total of 43,469 line items.

The quantities vary significantly by facility and product type, with St. Louis representing the largest volume facility, accounting for 9,725 pharmaceutical units (approximately 85% of total drug requirements) and 7,641 ancillary units. High-volume pharmaceutical requirements include Paclitaxel (1,613 units), Irinotecan HCL (724 units), Fluorouracil (676 units), and Etoposide (575 units). The document specifies that these figures represent estimated annual requirements for pricing and planning purposes only and do not constitute guaranteed purchase commitments. Actual quantities ordered will vary based on patient-specific needs and operational requirements, with the government retaining the right to order more or fewer quantities than estimated. All sterile products will be aseptically compounded in accordance with federal, state, and local laws and regulatory requirements, with the contractor responsible for appropriate storage and segregated shipment and labeling of hazardous versus non-hazardous compounds.